Immunic is trading 5.25% up in after-hours trading at $11.82 after a filing showed Bank of America increased its position by 80,724.2%, purchasing an additional 143,689 shares. - The disclosure appeared on September 13, 2026. - It came amid broader institutional and analyst interest in Immunic’s multiple-sclerosis program. - Phase 3 ENSURE trial results are expected by year-end; no new earnings release or regulatory decision was identified.